GlaxoSmithKline plc (LON:GSK) had its Overweight rating reiterated by Barclays

Analyst Ratings For GlaxoSmithKline plc (LON:GSK)

Today, Barclays reiterated its Overweight rating on GlaxoSmithKline plc (LON:GSK).

There are 13 Hold Ratings, 9 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on GlaxoSmithKline plc (LON:GSK) is Hold with a consensus target price of GBX 1,525.08 per share, a potential .

Some recent analyst ratings include

  • 8/10/2018-GlaxoSmithKline plc (LON:GSK) had its Overweight rating reiterated by Barclays
  • 8/7/2018-GlaxoSmithKline plc (LON:GSK) had its Buy rating reiterated by Liberum Capital
  • 8/7/2018-GlaxoSmithKline plc (LON:GSK) had its Buy rating reiterated by Shore Capital
  • 8/1/2018-GlaxoSmithKline plc (LON:GSK) had its Buy rating reiterated by Berenberg Bank with a GBX 1,790 price target
  • 8/1/2018-GlaxoSmithKline plc (LON:GSK) had its Hold rating reiterated by Deutsche Bank


    About GlaxoSmithKline plc (LON:GSK)
    GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; and a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

    Recent Trading Activity for GlaxoSmithKline plc (LON:GSK)
    Shares of GlaxoSmithKline plc closed the previous trading session at 576,00 −13,40 0,84 % with shares trading hands.

    An ad to help with our costs